Pembrolizumab for Early Triple-Negative Breast Cancer

Schmid P., Cortes J., Pusztai L., McArthur H., Kuemmel S., Bergh J., ...More

NEW ENGLAND JOURNAL OF MEDICINE, vol.382, no.9, pp.810-821, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 382 Issue: 9
  • Publication Date: 2020
  • Doi Number: 10.1056/nejmoa1910549
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), EMBASE, Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
  • Page Numbers: pp.810-821
  • Acibadem Mehmet Ali Aydinlar University Affiliated: Yes


Background Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early triple-negative breast cancer who have a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery is unclear.